...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of dermatology >Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy
【24h】

Sorafenib-induced psoriasis and hand-foot skin reaction responded dramatically to systemic narrowband ultraviolet B phototherapy

机译：索拉非尼诱导的牛皮癣和手足皮肤反应对全身性窄带紫外线B光疗反应显着

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Sorafenib (BAY 43-9006) is an inhibitor of multiple kinases, including Raf-1, B-Raf kinases, vascular endothelial growth factor receptor (VEGFR)-2 and -3, and platelet-derived growth factor receptor (PDGFR)-beta. As a multikinase inhibitor, sorafenib blocks the proliferation of tumor cells and angiogenesis, and is currently approved for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. However, several dermatological side-effects are associated with this drug, including facial erythema, hand-foot skin reaction (HFSR), subungual splinter hemorrhage, alopecia and pruritus. Here, we report a case of sorafenib-related HFSR and psoriasis that responded dramatically to systemic narrowband ultraviolet (UV)-B phototherapy.
机译：索拉非尼（BAY 43-9006）是多种激酶的抑制剂，包括Raf-1，B-Raf激酶，血管内皮生长因子受体（VEGFR）-2和-3和血小板源性生长因子受体（PDGFR）-beta 。作为多激酶抑制剂，索拉非尼可阻断肿瘤细胞的增殖和血管生成，目前已被批准用于治疗不可切除的肝细胞癌和晚期肾细胞癌。但是，该药物有几种皮肤病学副作用，包括面部红斑，手足皮肤反应（HFSR），趾下碎片出血，脱发和瘙痒。在这里，我们报告一例索拉非尼相关的HFSR和牛皮癣，对全身性窄带紫外线（UV）-B光疗反应显着。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号